What is Vertex Pharmaceuticals's finished goods?

Vertex Pharmaceuticals (VRTX) reported finished goods of $255.9M in Q1 2026.

How has Vertex Pharmaceuticals's finished goods changed year-over-year?

Vertex Pharmaceuticals's finished goods increased by 23.0% year-over-year, from $208M to $255.9M.

What is the long-term trend for Vertex Pharmaceuticals's finished goods?

Over 5 years (2020 to 2025), Vertex Pharmaceuticals's finished goods has grown at a 25.7% compound annual growth rate (CAGR), from $73.22M to $230.1M.

Vertex Pharmaceuticals VRTX Finished goods

Finished goods at other companies

Agios PharmaceuticalsAGIO

——

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

See full

Market cap$126.07B+17.7%

Enterprise value$122.55B+18.2%

P/E29.1×—

P/S10.3×+0.9×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's finished goods?: Vertex Pharmaceuticals (VRTX) reported finished goods of $255.9M in Q1 2026.
How has Vertex Pharmaceuticals's finished goods changed year-over-year?: Vertex Pharmaceuticals's finished goods increased by 23.0% year-over-year, from $208M to $255.9M.
What is the long-term trend for Vertex Pharmaceuticals's finished goods?: Over 5 years (2020 to 2025), Vertex Pharmaceuticals's finished goods has grown at a 25.7% compound annual growth rate (CAGR), from $73.22M to $230.1M.